ER-positive breast cancer cells are poised for RET-mediated endocrine resistance
Preprint
Abstract
The RET tyrosine kinase signaling pathway is involved in the development of endocrine resistant ER+ breast cancer. However, the expression of the RET receptor itself has not been directly linked to clinical cases of resistance, suggesting that additional factors are involved. We show that both ER+ endocrine resistant and sensitive breast cancers have functional RET tyrosine kinase signaling pathway, but that endocrine sensitive breast cancer cells lack RET ligands that are necessary to drive endocrine resistance. Transcription of one RET ligand, GDNF, is necessary and sufficient to confer resistance in the ER+ MCF-7 cell line. In patients, RET ligand expression predicts responsiveness to endocrine therapies and correlates with survival. Collectively, our findings show that ER+ tumor cells are “poised” for RET mediated endocrine resistance, expressing all components of the RET signaling pathway, but endocrine sensitive cells lack high expression of RET ligands that are necessary to initiate the resistance phenotype.Keywords
All Related Versions
- Published version: PLOS ONE, 13 (4), e0194023.
This publication has 42 references indexed in Scilit:
- Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenograftsOncotarget, 2016
- Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cellsEMBO Molecular Medicine, 2013
- GDNF–RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase InhibitorsCancer Research, 2013
- Enhancer transcripts mark active estrogen receptor binding sitesGenome Research, 2013
- High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagyProceedings of the National Academy of Sciences, 2011
- Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistanceOncogene, 2010
- Widespread transcription at neuronal activity-regulated enhancersNature, 2010
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Similarities and distinctions in the mode of action of different classes of antioestrogens.Endocrine-Related Cancer, 2000
- The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by TamoxifenCell, 1998